Comprehensive profile
The product page states assessment of resistance markers across 18 drugs.
Tuberculosis genomics
See more of the resistance story.
A whole-genome sequencing approach to TB drug resistance, strain information, and mixed infection assessment.
Discuss this solution ↗ΩTB / SIGNAL PROFILEGENOMICS → CLINICAL CONTEXT
18 drugsDrug resistance profile including bedaquiline and delamanid
99.8%Specificity stated on the existing product page
>10,000Genomes used in validation, as reported by the company
TUBERCULOSIS GENOMICS
The full resistance
picture.
ΩTB® is described on the original site as a universal TB drug resistance test. It evaluates resistance markers for 18 antibiotics, including bedaquiline and delamanid, while adding strain information, phylogenetic reconstruction, and mixed infection assessment.
The original page cites 2.7 million Indian cases out of 10 million cases worldwide. Those figures are historical site content, not current surveillance data.
India
27%
Rest of world
33%
China
9%
Indonesia
8%
Philippines
6%
Pakistan
6%
Nigeria
4%
Bangladesh
4%
South Africa
3%
DRUG COVERAGE
A broader resistance
assessment.
| Test | Antibiotic coverage |
|---|---|
| ΩTB® | 18 antibiotics, including bedaquiline and delamanid |
| Culture test | 13–15 antibiotics |
| CBNAAT | 1–2 antibiotics |
| LPA | Targeted first-line or second-line drugs |
ΩTB® ASSESSMENT PROFILE
Six ways to read
the case.
01
Resistance markers across 18 antibiotics
02
99.8% specificity stated by HaystackAnalytics
03
85–98% sensitivity stated by HaystackAnalytics
04
Phylogenetic reconstruction
05
Mixed infection and NTM/MOTT co-infection identification
06
Strain information
HaystackAnalytics reports 99.8% specificity, 85–98% sensitivity, validation on more than 10,000 genomes and more than 1,000 clinical samples, and a test cost less than or comparable to culture testing. These are company-stated claims.
PRACTICAL BENEFITS
Look further than
a single marker.
Beyond resistance
Strain information and phylogenetic reconstruction can add context to a result.
Mixed infections
Designed to distinguish mixed infection and co-infections, including NTM/MOTT.
COMMON QUESTIONS
A little more
clarity.
Specifications are stated on HaystackAnalytics' original website. Confirm current availability and clinical use with the team.
What is ΩTB? +
ΩTB is HaystackAnalytics’ genomics-based tuberculosis drug resistance test. It is designed to assess resistance markers and provide strain information.
How many drugs does ΩTB assess? +
HaystackAnalytics lists 18 antibiotics, including bedaquiline and delamanid, on its existing ΩTB product page.
Can ΩTB identify mixed infections? +
The company says its assessment profile can identify mixed infections and co-infections, including NTM/MOTT.
LET'S MOVE THE FIELD FORWARD
Better answers begin
with a conversation.
Explore how genomics can fit your clinical or laboratory workflow.
Talk to our team ↗